China's HBM climbs on regulator's nod on application of new cancer drug
10/06/2026 06:57
BUZZ-China's HBM climbs on regulator's nod on application of new cancer drug ** Shares of Chinese immuno-oncology and immunology diseases therapeutics developer HBM Holdings 2142.HK climb 5.1% to HK$10.02, on track for the biggest one-day pct gain since June 4
** Stock on course to snap three straight sessions of losses
** HBM says China's regulator National Medical Products Administration (NMPA) has accepted the Investigational New Drug application for HBM7004 in treatment of advanced solid tumors
** YTD, stock down 18.8%, Hong Kong Biotech Index .HSBIO down 15.7%
(Reporting by Donny Kwok)
Recent news on HBM Holdings
See all newsBrief: HBM Holdings Says NMPA Approves Batoclimab Injection For Generalized Myasthenia Gravis
HBM climbs on development of AI biology foundation model
Brief: HBM Holdings' Unit Develops World's First Language Model For Fully Human Heavy-Chain-Only Antibodies
Brief: Hbm Holdings Says Solstice Oncology Launches Series A Financing Round
HK-listed HBM climbs on initiating next phase of asthma drug study